Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI) (EPHICACI)

15 de setembro de 2026 atualizado por: Universitaire Ziekenhuizen KU Leuven

Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections

EPHICACI is a multicenter, prospective study that continues and expands the monocentric PHAGEFORCE registry initiated at UZ Leuven. In Belgium, phage therapy can be applied as standard-of-care only in patients with difficult-to-treat infections where no curative antibiotic and/or surgical alternatives are available ('last-resort cases'). A multidisciplinary phage task force, the Coordination group for Bacteriophage therapy Leuven (CBL), evaluates eligible patients, tests pathogen susceptibility, and sets up standardized treatment protocols. With EPHICACI, this approach is extended to multiple Belgian expert centers to increase patient enrollment while upholding stringent eligibility criteria. The study aims to gain insight into the safety, efficacy, biodistribution and mechanisms of action of phage therapy, and to optimize its use across five medical disciplines (with distinct routes of administration). In addition, EPHICACI integrates machine learning-based phage-bacteria interaction analyses to guide personalized phage selection, and includes health economic evaluations to support evidence-based implementation and reimbursement strategies.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Patients with difficult-to-treat musculoskeletal infections, chronic rhinosinusitis, persistent bacteremia, pulmonary infections associated with cystic fibrosis or bronchiectasis, or hidradenitis suppurativa, for whom no standard (curative) treatment options are available, are eligible for phage therapy. Patient eligibility is assessed by the multidisciplinary Coordination group for Bacteriophage therapy Leuven (CBL), in collaboration with multiple Belgian expert centers. If phages with activity against the isolated bacterial strain are identified and the patient meets all inclusion criteria, a phagogram is performed. Based on these results, patients are either assigned to receive phage therapy or remain in the control group receiving best available non-curative treatment. In both groups, standardized clinical, microbiological and health economic data are collected prospectively using REDCap.

Tipo de estudo

Observacional

Inscrição (Estimado)

100

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Leuven, Bélgica, 3000
        • Recrutamento
        • University Hospitals Leuven
        • Contato:
        • Contato:
        • Investigador principal:
          • Willem-Jan Metsemakers, MD, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

All patients:

  • Diagnosed with an MSI or CRS or persistent bacteremia or or pulmonary infection (cystic fibrosis/bronchiectasis) or HS and
  • For whom all previous treatments (surgical and antibiotic) have failed or for whom no other treatment options are available (i.e., last resort cases, based on the assessment of the local phage hub), for example in case of bacterial resistance. And
  • Of whom the pathogen causative for the infection is one for which phages are available in the phage bank, and
  • Who have given informed consent to have their data collected in a patient registry.

Descrição

Inclusion criteria

  • Diagnosed with an MSI or CRS or persistent bacteremia or pulmonary infection (cystic fibrosis/bronchiectasis) or HS and
  • For whom all previous treatments (surgical and antibiotic) have failed or for whom no other treatment options are available (i.e., last resort cases, based on the assessment of the local phage hub), for example in case of bacterial resistance. And
  • Of whom the pathogen causative for the infection is one for which phages are available in the phage bank, and
  • Who have given informed consent to have their data collected in a patient registry

Exclusion Criteria:

All patients:

  • With an infectious disease other than those mentioned above, and/or
  • For whom standard treatment alternatives are still available. And/or
  • Of whom the pathogen causative for the infection is not one for which phages are available in the phage bank. And/or
  • Who refused to give their informed consent

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Phage treated group

Patients whose isolated pathogens are susceptible to the available phages and who have no alternative curative treatment options are included in the phage-treated group. The local phage hub, in consultation with the Phage Consortium, will design the phage therapy treatment plan (local, inhalation, or intravenous) on top of standard surgical and/or antimicrobial care. The treatment plan is documented in the patient's medical file. Patients undergo monitoring according to the phage therapy protocol and follow-up according to standard care for phage-treated patients.

Prospective data collection prior to, during and after phage treatment.

Control group

Patients whose isolated pathogens are not susceptible to available phages, or for whom phage therapy is not indicated, are included in the control group. These patients receive standard surgical and/or antimicrobial care as determined by the local phage hub. Monitoring and follow-up are according to the standard of care for the underlying pathology.

Prospective data collection prior to, during and after standard infection treatment.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Disease-free period
Prazo: Until 1 year after treatment

In MSI patients

Until 1 year after treatment
Smell test
Prazo: Until 1 year after treatment

16-point Sniffin' Sticks test in CRS patients

Until 1 year after treatment
Radiological scores
Prazo: Until 1 year after treatment

Lund-Mackay CT score in CRS patients

Until 1 year after treatment
Endoscopic scores
Prazo: Until 1 year after treatment

Lund-Kennedy score and Modified Davos score in CRS patients

Until 1 year after treatment
Time to clearance of infection
Prazo: Until 1 year after treatment, daily during hospitalization until infection clearance

In patients with Persistent Bacteremia

Until 1 year after treatment, daily during hospitalization until infection clearance
Overall survival
Prazo: Until 1 year after treatment

Does the patient survive (for patients with Persistent Bacteremia)

Until 1 year after treatment
SOFA score
Prazo: Baseeline and daily during hospitalization until discharge, for up to 12 weeks after cessation of phage therapy; thereafter at 6 months and 1 year after cessation of phage therapy.

Sequential Organ Failure Assessment (SOFA) score in patients with persistent bacteremia, assessed to monitor changes in organ dysfunction during hospitalization.

Baseeline and daily during hospitalization until discharge, for up to 12 weeks after cessation of phage therapy; thereafter at 6 months and 1 year after cessation of phage therapy.
Tolerance of the intervention
Prazo: During scheduled phage therapy (up to 6 weeks)

Proportion of patients with chronic pulmonary infection able to complete the planned phage therapy without treatment discontinuation due to adverse reactions or pulmonary exacerbations.

During scheduled phage therapy (up to 6 weeks)
Sputum culture conversion assessed by microbiological culture
Prazo: Days 1-4 of phage therapy, weekly during phage therapy for up to 6 weeks, and at 6 and 12 months after completion of phage therapy.

Proportion of patients with chronic pulmonary infection with conversion from a positive sputum culture for the targeted bacterial pathogen at baseline to a negative sputum culture for the targeted bacterial pathogen after phage therapy.

Days 1-4 of phage therapy, weekly during phage therapy for up to 6 weeks, and at 6 and 12 months after completion of phage therapy.
Within-subject change in the number of positive cultures
Prazo: At 6 and 12 months compared to 12 months prior to therapy

In patients with Chronic Pulmonary Infection

At 6 and 12 months compared to 12 months prior to therapy
Within-subject change in the number of pulmonary exacerbations requiring additional antibiotic therapy or hospitalization.
Prazo: At 6 and 12 months

In patients with Chronic Pulmonary Infection

At 6 and 12 months
Clinical response measured by forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC).
Prazo: Until 1 year after treatment

In patients with Chronic Pulmonary Infection

Until 1 year after treatment
Improvement in IHS4 score
Prazo: Until 1 year after treatment

In HS patients

Until 1 year after treatment
Improvement in ANF count using HiSCR50 and HiSCR75
Prazo: Until 1 year after treatment

In HS patients

Until 1 year after treatment
Reduction in flare incidence compared to the 12 weeks prior to treatment.
Prazo: Until 1 year after treatment

In HS patients

Until 1 year after treatment
Bacterial load in sinonasal material measured by quantitative microbiological culture
Prazo: Until 1 year after treatment

Bacterial load of the targeted bacterial pathogen in sinonasal samples from CRS patients quantified by microbiological culture and expressed as colony-forming units (CFU).

Until 1 year after treatment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
PROMIS global health
Prazo: until 1 year after treatment

specific to MSI, CRS, Chronic Pulmonary Infection

until 1 year after treatment
PROMIS pain interference
Prazo: until 1 year after treatment

specific to MSI, CRS

until 1 year after treatment
PROMIS physical function
Prazo: until 1 year after treatment

specific to MSI, CRS

until 1 year after treatment
iMCQ
Prazo: until 1 year after treatment

specific to MSI, CRS, Persistent bacteremia

until 1 year after treatment
iPCQ
Prazo: until 1 year after treatment

specific to MSI, CRS, Persistent bacteremia

until 1 year after treatment
EQ-5D-5L
Prazo: until 1 year after treatment

specific to MSI, CRS, Persistent bacteremia, Chronic Pulmonary Infection, HS

until 1 year after treatment
SNOT-22
Prazo: until 1 year after treatment

specific to CRS

until 1 year after treatment
VAS pain
Prazo: until 1 year after treatment

specific to CRS, HS

until 1 year after treatment
CF-Q
Prazo: until 1 year after treatment

specific to Chronic Pulmonary Infection

until 1 year after treatment
Bronchiectasis QoL
Prazo: until 1 year after treatment

specific to Chronic Pulmonary Infection

until 1 year after treatment
FEV1
Prazo: until 1 year after treatment

specific to Chronic Pulmonary Infection

until 1 year after treatment
FVC
Prazo: until 1 year after treatment

specific to Chronic Pulmonary Infection

until 1 year after treatment
DLQI
Prazo: until 1 year after treatment

specific to HS

until 1 year after treatment
HiSQoL
Prazo: until 1 year after treatment

specific to HS

until 1 year after treatment
Systemic and local phage exposure per route of administration
Prazo: until 1 year after treatment

Specific to MSI, CRS, Chronic pulmonary infection, HS, bacteremia

until 1 year after treatment
Duration of phage activity in blood or locally
Prazo: until 1 year after treatment

Phage kinetics / pharmacology

until 1 year after treatment
Change in phage-neutralizing activity measured by serum neutralization test
Prazo: until 1 year after treatment

Phage-neutralizing activity in serum will be assessed using a serum neutralization test (adapted Adams protocol) by measuring the reduction in viable phage titer after incubation with patient serum compared with baseline. Results will be expressed as the log10 reduction in phage titer.

until 1 year after treatment
Change in bacterial load of the targeted pathogen measured by quantitative microbiological culture
Prazo: until 1 year after treatment

Change in bacterial load of the targeted bacterial pathogen in clinical samples collected during and after phage therapy, quantified by microbiological culture and expressed as CFU per mL.

until 1 year after treatment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Willem-Jan Metsemakers, MD, PhD, UZ / KU Leuven

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de junho de 2021

Conclusão Primária (Estimado)

31 de dezembro de 2028

Conclusão do estudo (Estimado)

31 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

4 de abril de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de abril de 2024

Primeira postagem (Real)

16 de abril de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

21 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de setembro de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .